// App-Quantinova.ai

Filters

Biomarkers











Conference Name











Country

























Company

Search valid company name..

Conference Year













Drug











Disease











Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























914 Abstracts

Bone Marrow Complications in Idiopathic Pulmonary Fibrosis Lung Transplant Recipients

S. Hannan - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Clinical Utility Analysis of the Envisia Genomic Classifier

J. Chung - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Idiopathic pulmonary fibrosis

N/A

129Xenon MR Imaging and Spectroscopic Signatures to Differentiate Pulmonary Arterial Hypertension from Other Heart and Lung Disease

E. Bier - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Idiopathic pulmonary fibrosis

N/A

Assessment of a Cough Visual Analogue Scale with Validated Instruments in Patients with Idiopathic Pulmonary Fibrosis

S. S. Jacobs - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Machine Learning Models for Predicting Mortality in Idiopathic Pulmonary Fibrosis (IPF) Patients

Z. Zhu - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

a Novel, Chitinase Inhibitor for Treatment of Interstitial Lung Diseases

R. Dyjas - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Idiopathic pulmonary fibrosis

N/A

Based Idiopathic Pulmonary Fibrosis Cohort

D. Zhu - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Advanced Care Planning (ACP) Model in Idiopathic Pulmonary Fibrosis

A. Daoud - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Temporal Echocardiographic Assessment of Pulmonary Hypertension in Patients with Idiopathic Pulmonary Fibrosis Treated with Nintedanib, Pirfenidone and Other Agents

M. Tahara - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Idiopathic pulmonary fibrosis

Pirfenidone

Home Deaths in Idiopathic Pulmonary Fibrosis: An Autopsy Study

E. Wall - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Idiopathic pulmonary fibrosis

N/A

Monitoring Cough in a Preclinical Guinea Pig Model of Idiopathic Pulmonary Fibrosis

J. H. A. Miles - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

Bleomycin

Pharmacokinetics and Safety of Pirfenidone Following Inhaled Delivery to Sheep: A Viable Approach to Treating Idiopathic Pulmonary Fibrosis

M. Surber - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

Pirfenidone

Use of Quantitative CT to Determine Disease Extent and Identify UIP Pattern in Rheumatoid Arthritis ILD

S. M. Humphries - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Idiopathic pulmonary fibrosis

Pirfenidone

Induced Pulmonary Inflammation and Fibrosis in Rats

Q. Ye - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

Pirfenidone

Forming Cells Isolated from Idiopathic Pulmonary Fibrosis Patients Might Contribute to Their Pathogenicity

A. Blandinieres - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

Sulfasalazine

The IRE/XBP1 Pathway Is Activated in Alternatively Activated Macrophages in Interstitial Fibrotic Lung Disease

M. Vierhout - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

Phorbol myristate acetate

PKcs Modulates Progenitor Cell Proliferation and Fibroblast Senescence in Idiopathic Pulmonary Fibrosis

M. Hohmann - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Epithelial Cell Transforming Sequence 2 Contributes to Alveolar Epithelial Cell Reprogramming in Idiopathic Pulmonary Fibrosis

K. Heinzelmann - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

Bleomycin

CCL2/12 from Injured Alveolar Epithelial Cells Initiated and Promoted Progressive Pulmonary Fibrosis

J. Yang - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

Bleomycin

250, and Its Efficacy for Treatment of Idiopathic Pulmonary Fibrosis (IPF)

A. Shibata - American Thoracic Society (ATS) , 2019

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Idiopathic pulmonary fibrosis

N/A

Copyright © 2026. QuantiNova All rights reserved